Full Title: Improving Outcomes through Collaboration In Osteosarcoma
Status: Active, Recruiting
Age Range: All ages
Locations:
- Beatson West Of Scotland Cancer Centre, Glasgow
- Nottingham University Hospitals NHS Trust, Nottingham
- Churchill Hospital, Oxford
- Weston Park Hospital, Sheffield
- Clatterbridge Cancer Centre, Wirral
- University College Hospital, London
- Queen Elizabeth Hospital, Birmingham
- Leicester Royal Infirmary, Leicester
- Sheffield Children's Hospital, Sheffield
- Southampton General Hospital, Southampton
- Addenbrooke's Hospital, Cambridge
- Birmingham Children's Hospital, Birmingham
- Clarendon Wing, Leeds General Infirmary, Leeds
- Nottingham University Hospitals NHS Trust - Queen's Medical Centre Campus, Nottingham
- John Radcliffe Hospital, Oxford
- Renamed University Hospital, Leeds
- Alder Hey Children's NHS Foundation Trust, Liverpool
- Royal Hospital For Sick Children, Glasgow
- Royal Manchester Children's Hospital, Manchester
- The Royal National Orthopaedic Hospital, Stanmore
- Robert Jones & Agnes Hunt Orthopaedic Hospital, Oswestry
- The Christie, Manchester
- Royal Aberdeen Children's Hospital, Aberdeen
- Bristol Haematology & Oncology Centre, Bristol
- Royal Hospital For Sick Children, Edinburgh
- Noahs Ark Childrens Hospital For Wales, Cardiff
Registry Number: NCT04132895
Osteosarcoma is the most common form of bone sarcoma in children and teenagers and is usually treated with surgery and a standard first line chemotherapy regime called MAP chemotherapy in this group of patients. Osteosarcoma is unusual in that it has a second peak in incidence in older adults over 50 years and a standard treatment for this group of patients has not been established. Unfortunately, in some patients, it does not respond to treatment or returns after treatment and we currently don't know why and how to stop this happening.
ICONIC aims to recruit osteosarcoma patients of any age and from across the UK and Ireland, where clinical data, such as the stage of disease at diagnosis, the treatment the patient receives and their response to treatment. Tissue samples will also be collected from patients, if they agree, which will be analysed by researchers. By linking a patient's clinical data to what is happening inside their tumour samples, it provides researchers with an invaluable opportunity to understand why some patients respond to treatment and some don't and what causes osteosarcoma to spread to other parts of the body.
The study will also look at how patients are diagnosed and quality of life measures both during and after treatment.
The trial is classed as observational at this stage, meaning that it does not include any novel treatments, however, it has been developed as a framework to allow any new, novel treatments to be added as they become available.
The trial has been funded by the Bone Cancer Research Trust.
Donate now (This link opens in a new window) More about Osteosarcoma